Molecular biotherapy with human monoclonal antibodies |
| |
Authors: | M C Glassy R O Dillman |
| |
Affiliation: | Biotherapeutics, Inc., La Jolla, CA. |
| |
Abstract: | Human monoclonal antibodies are theoretically superior to murine monoclonal antibodies for many reasons. However, there are many hurdles in their preparation and clinical use, including the source of B lymphocytes, immortalization techniques, screening methods, scale-up limitations, purification steps, and the problems associated with conjugating to cytotoxic substances. Chimeric mouse/human antibodies are an alternative approach. Optimum clinical utilization will require a better understanding of target antigens and the ability to formulate cocktails. |
| |
Keywords: | |
|
|